http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-066111-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| filingDate | 2008-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-066111-A1 |
| titleOfInvention | TRICYCLE COMPOUND OF IMIDAZOL, ITS USE TO PREPARE A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND INTERMEDIATE COMPOUNDS IN THE SYNTHESIS OF SUCH COMPOUND |
| abstract | Tricyclic imidazole compound of formula (1) or a pharmaceutically acceptable salt and / or N-oxide thereof, wherein: Z1 and Z2 are independently selected from CH and N; R1a and R1b are independently selected from hydrogen; halogen; cyano; C1-6 alkyl; C1-6 alkylthio; trifluoromethyl; trifluoromethoxy; carboxy; hydroxy optionally substituted with C1-6 alkyl or C1-6 alkoxy-substituted C1-6 alkyl; C1-6 alkoxy-substituted C1-6 alkyl; C1-6 hydroxyalkyl; an amino-optionally N-substituted group with one or two C1-6 alkyl, formyl, C1-6 alkylcarbonyl or C1-6 alkyl sulfonyl groups; and aminocarbonyl wherein the amino group is optionally substituted with C1-4 alkyl; with the proviso that R1a and R1bsean when Z2 or Z1 is N, respectively; R 2 is hydrogen or C 1-4 alkyl, or together with R 6 form Y as defined below; A is a group of formula (2) or (3) where: R3 is as defined for R1a and R1b or is oxo and n is 1 or 2: or A is a deformula group (4); W1, W2 and W3 are CR4R8 or W2 and W3 are CR4R8 and W1 represents a link between W3 and N, X is O, CR4R8, or NR6; an R4 is as defined for R1a and R1b and the rest and R8 are hydrogen or an R4 and R8 are together oxo and the rest are hydrogen; R6 is hydrogen or C1-6 alkyl; or together with R2 form Y; R7 is hydrogen; halogen; hydroxy optionally substituted with C1-6 alkyl; or C1-6 alkyl; Y is CR4R8CH2, CH2CR4R8, (C = O); CR4R8, CR4R8 (C = O); or (C = O) CR4R8 or when X is CR4R8, R8 and R7 together represent a link; U is selected from CO and CH2 and R5 is an optionally substituted bicyclic, carbocyclic or heterocyclic ring system (5), containing up to four heteroatoms in each ring, in which at least one of the rings (a) and (b) is aromatic; X1 is C or N when it is part of an aromatic ring, or CR14 when it is part of a non-aromatic ring; X2 is N, NR13, O, S (O) x, CO or CR14 when it is part of an aromatic or non-aromatic ring, or it may also be CR14R15 when it is part of a non-aromatic ring; X3 and X5 are independently N or C; Y1 is a linker group of 0 to 4 atoms in which each atom is independently selected from N, NR13, O, S (O) x, CO and CR14 when it is part of an aromatic or non-aromatic ring or can additionally be CR14R15 when it forms part of a non-aromatic ring; Y2 is a linking group of 2 to 6 atoms, in which each atom of Y2 is independently selected from N, NR13, O, S (O) x, CO, CR14 when it is part of an aromatic or non-aromatic ring or can be additionally CR14R15 when part of a non-aromatic ring; each of R14 and R15 is independently selected from: H; C1-4 alkylthio; halo; C1-4 carboxyalkyl; C1-4 alkyl; C1-4 alkoxycarbonyl; C1-4 alkylcarbonyl; C1-4 alkoxy-C1-4 alkyl; hydroxy; C1-4 hydroxyalkyl; C1-4 alkoxy; nitro; cyano; carboxy; amine or aminocarbonyl optionally mono or disubstituted with C1-4 alkyl; or R14 and R15 may jointly represent oxo; each R13 is independently H; trifluoromethyl; C1-4 alkyl optionally substituted with hydroxy, C1-6 alkoxy, C1-6thio alkyl, halo or trifluoromethyl; C2-4 alkenyl; C1-4 alkoxycarbonyl; C1-4 alkylcarbonyl; C1-6 alkyl sulfonyl; aminocarbonyl where the amino group is optionally mono or disubstituted with C1-4 alkyl; and each x is independently 0, 1 or 2. Its use to prepare a medicament useful for the treatment of bacterial infections in mammals and pharmaceutical composition comprising it. Intermediate compounds useful in the synthesis of said compound. |
| priorityDate | 2007-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.